| Followers | 1129 |
| Posts | 32637 |
| Boards Moderated | 2 |
| Alias Born | 01/11/2016 |
Saturday, March 02, 2019 4:58:00 PM
Yes, market capitalization on BPTH is currently sitting on 13.5 million and yes 1.7 million shares outstanding and just over 500,000 shares in the public float. The public float is what the retail can buy and sell in the market place. The outstanding shares are what the institutions and the insiders own, so take the public float and minus the outstanding shares and you can up with around 1.2 million shares that are owned by institutions and insiders and I am sure they are mostly restricted for at least 6 months to a year. So essentially the float is what is being traded now, not the outstanding. Market cap is severely low, I would not doubt market cap to be around 30-50 million dollars sometime next week and if the data is good, it should go to at least 100 million. Those figures are not even considered in to the buyout scenario, buyout could be at least 500 million dollars, if they have a viable science.
https://finance.yahoo.com/quote/BPTH/key-statistics?p=BPTH
https://finance.yahoo.com/quote/BPTH/key-statistics?p=BPTH
Recent BPTH News
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 07/11/2025 08:44:58 PM
- Life Sciences Investor Forum: Now Available for Online Viewing • GlobeNewswire Inc. • 06/13/2025 12:35:00 PM
- Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum • GlobeNewswire Inc. • 06/09/2025 11:00:00 AM
- Bio-Path Holdings Provides Clinical and Operational Update • GlobeNewswire Inc. • 06/03/2025 11:00:00 AM
- Form 253G3 - • Edgar (US Regulatory) • 06/02/2025 08:35:21 PM
- Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 • GlobeNewswire Inc. • 05/22/2025 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2025 12:15:15 PM
- Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients • GlobeNewswire Inc. • 05/01/2025 11:00:00 AM
- Form 1-A - Offering Statement [Regulation A] • Edgar (US Regulatory) • 04/11/2025 08:28:53 PM
